Carlos Mendoza Santiesteban, MD
Neuro-ophthalmology · Miami, FLNPI 1235682311
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,625 of the $3,265 with a category attached, or 80.4%. PTC Therapeutics, Inc. accounts for 80.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $2,724 and has fallen 97.2% since, to $77 in 2025.
Across 17 payments — averaging $192.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- PTC Therapeutics, Inc.$3K
- Spark Therapeutics, Inc.$172
- EMD Serono, Inc.$125
- Amgen$104
- Biotissue Holdings Inc.$93
- Tarsus Pharmaceuticals, Inc.$77
- plus $69 from 2 others
What the payments were for
- Consulting fees$2,62580%
- Food & beverage$64020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| PTC Therapeutics, Inc. | 1 | $2,625 |
| Spark Therapeutics, Inc. | 2 | $172 |
| EMD Serono, Inc. | 1 | $125 |
| Amgen(2 entities) | 4 | $104 |
| Biotissue Holdings Inc. | 5 | $93 |
| Tarsus Pharmaceuticals, Inc. | 2 | $77 |
| Alcon | 1 | $52 |
| Recordati_rare_diseases_inc. | 1 | $17 |
How this compares
Too few neuro-ophthalmology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acetazolamide ErAcetazolamide | 13 | $2,020 |
| Pyridostigmine Bromide | 11 | $769 |
| Brimonidine Tartrate | 79 | $606 |
| Latanoprost | 49 | $263 |
| Dorzolamide Hcl | 11 | $197 |
| Prednisone | 20 | $176 |
| Timolol Maleate | 16 | $148 |
Paid to pharmacies, not to this prescriber.
Other neuro-ophthalmology in Miami
- Byron LamMiami$86K
- Hong JiangMiami$508
- Pablo RavennaMiami$104
- Daniela TeijeloMiami$62
- Bryan RiggealJacksonville$20K
- Hazem SamyJacksonville$6K
- David AuerbachMaitland$6K
- Shauna BerryBonita Springs$2K
- Bryce BuchowiczGainesville$394
- Aishwarya SriramTampa$371
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.